PET/MRI as a Predictor of Response to Pre-op Chemoradiation in Resectable Rectal Cancer: a Pilot Study

Completed

Conditions studied: Rectal Carcinoma

In brief

This is a single arm, single center pilot study of 40 patients with uT3N0 or uT1-3N+ rectal cancer receiving pre-operative chemoradiation. Subjects will undergo PET/MRI scans before and after surgery.

Key facts

Study ID

NCT01751516

Run by

UNC Lineberger Comprehensive Cancer Center

People needed

8

Starts

2012-10-01

Expected to finish

2018-03-04

Last updated by the study team

2021-01-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Low-lying, low- to moderate-risk pathologically-confirmed rectal cancer (stage uT3n) or uT1-3N+
• Negative workup for distant disease
• > 18 years of age
• Pre-treatment workup completed including:
• history and physical
• CT or MRI of the abdomen and pelvis
• endoscopic tumor evaluation (biopsy, blood work to assess CEA and hematopoietic, renal and liver function)
• if female of child-bearing age, negative pregnancy test
• Recommendation to undergo preoperative concurrent chemoradiation, as determined by the treating physician
• Informed consent reviewed and signed

You may not qualify if…

• Not deemed a candidate for preoperative chemoradiation for medical reasons, such as uncontrolled infection (including HIV), uncontrolled diabetes mellitus or cardiac disease
• Hemoglobin ≤ 10.0 g/dL (transfusion allowed to achieve or maintain levels)
• ANC ≤ 1,500/cubic mm³
• Platelet count ≤ 100,000/mm³
• ALT and AST ≥ 2.5 times upper level of normal (ULN)
• Alkaline phosphatase ≥ 2.5 times ULN
• Total bilirubin ≥ 1.5 times ULN
• Creatinine clearance < 50 mL/min
• Creatinine ≥ 1.5 times ULN
• Not deemed a candidate for concurrent preoperative chemoradiation for social reasons, such as psychiatric illness
• Not deemed a surgical candidate
• Currently active second malignancy, except non-melanoma skin cancer, non-invasive bladder cancer, low risk adenocarcinoma of the prostate and carcinoma in situ of the cervix
• Previous pelvic radiation therapy
• History of severe reaction to gadolinium
• Inability to tolerate MRI (e.g., inability to lie flat for > 1 hour)
• Presence of a pacemaker, intracranial aneurysm clip, bladder stimulator, cochlear implant or metal near eyes
• Body Mass Index (BMI) > 35
• Pregnant or lactating female

Where it is running

• University of North Carolina-Chapel Hill — Chapel Hill, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.